METHOD OF DIFFERENTIATED TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOSARCOMAS OF LYMPHOID ORGANS IN ADULTS Russian patent published in 2011 - IPC A61K31/196 A61K31/475 A61K31/704 A61K31/675 A61K31/427 A61K31/7064 A61K31/573 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to oncohematology and can be used for treatment of diffuse large B-cell lymphosarcomas (DLBCL) of lymphoid organs in adults. The method involves pre-phase chemotherapy of sequential 6-fold block radical chemotherapy A-B-A-B-C-A or A-B-A-B-A-B. The block A is performed by the intravenous introduction of: methotrexate 1500 mg/m² and vincristine 2 mg on the 1st day, doxorubicine 25 mg/m² on the 1st and 2nd days, vepezide 100 mg/m² and cytosar 150 mg/m² on the 4th and 5th days only, and iphosphamide 800 mg/m² intravenously, dexamethasone 20 mg in tablets on the 1-5th days. Further, the block B follows by the intravenous introduction of: methotrexate 1500 mg/m² and vincristine 2 mg on the 1st day, doxorubicine 25 mg/m² on the 4th and 5th days only, cyclophosphan 200 mg/m² and dexamethasone 20 mg in tablets on the 1-5th days, then another 2 blocks A and B follow. In the presence of a complete remission, another 2 blocks A-B are required, and in the absence thereof, the block C is performed by the intravenous introduction: methotrexate 1500 mg/m² and vinblastine 10 mg on the 1st day, cytosar 2000 mg/m² 2 times a day on the 2nd and 3rd days, vepezide 150 mg/m² on the 3rd, 4th and 5th days, dexamethasone 20 mg in tablets on the 1-5th days, and then in the presence of the complete remission, the block A is performed. The therapeutic course is 4.5-5 months, every 21 days.

EFFECT: method allows higher clinical effectiveness in DLBCL, reduced recurrent cases, higher survival rate.

2 dwg, 3 ex